The Dose Finding Study of DAOIB Added to tDCS for AD
Key facts
- Who runs it
- Chang Gung Memorial Hospital
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 140 people, planned
- Starts
- Jan 2027
- Expected to end
- Dec 2028
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- DAOIB
- Record updated
- 20 March 2026
- Why it stopped
- The trial was suspended due to the budget issue
Who can take part
- Age
- 50 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
- MMSE between 10-26
- CDR 1 or 0.5
Who cannot take part
- Parkinson disease, epilepsy, dementia with psychotic features
- Major depressive disorder
- Major physical illnesses
- Severe visual or hearing impairment
- Hachinski Ischemic Score > 4
- Substance abuse/dependence
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10 sessions in total) during the first 2 weeks of the study, and will also be allocated randomly to either of 4 treatment groups for 24 weeks: (1) Dose A group; (2) Dose B group; (3) Dose C group; (4) placebo group. We will assess the patients every 8 weeks during the treatment period (weeks 0, 10, 18, and 26). We hypothesize that augmentation with certain dose of DAOIB will yield better effect than tDCS alone in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.
The 4 groups in the trial
- tDCS+Dose ATreatment being tested
Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
Treatment: DAOIB
- tDCS+Dose BTreatment being tested
Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
Treatment: DAOIB
- tDCS+Dose CTreatment being tested
Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
Treatment: DAOIB
- tDCS+placeboPlacebo, for comparison
Drug: Placebo Placebo Device: tDCS tDCS
Treatment: DAOIB
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Dose Finding Study of Sodium Benzoate Added to tDCS for the Treatment of Early-phase Alzheimer's Disease
- Record updated
- 20 March 2026